mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang, Zhiyong, Martin, Daniel, Molinolo, Alfredo A., Patel, Vyomesh, Iglesias-Bartolome, Ramiro, Sol Degese, Maria, Vitale-Cross, Lynn, Chen, Qianming, Gutkind, J. Silvio
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133928/
https://ncbi.nlm.nih.gov/pubmed/25099740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju215
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados